Mhedzisiro yeakawanda-epakati Phase III kliniki yekuedza yakaratidza kuti kana varwere vakwegura vane chronic lymphocytic leukemia ( CLL ) inorapwa neiyo nyowani yakanangwa nemishonga ibrutinib kana ichienzaniswa neyaimbove inowanzo shanda regimen-bendamustine inosanganiswa ne rituximab Chirwere chichiwedzera mwero we mAb wakadzikiswa zvakanyanya, izvo zvakare zvinoratidza kuti rituximab inosanganiswa neibrutinib haizounze mamwe mabhenefiti pamusoro pe ibrutinib chete.
CLL ndiyo inonyanya kuzivikanwa kenza yeleukocyte kune vakwegura. Muna 2016, US FDA yakabvumira ibrutinib semutsetse wekutanga kurapwa kweCLL. Zvidzidzo zvakapfuura zvakaratidza kuti ibrutinib inoshanda zvakanyanya kupfuura imwe chemotherapeutic drug chlorambucil, asi hapana zvidzidzo zvakaenzanisa ibrutinib ne bendamustine pamwe ne rituximab.
Muedzo wakanyoresa varwere vechikuru mazana mashanu nemakumi manomwe nenomwe vane makore epakati emakore makumi manomwe nerimwe. 547/71 vakapihwa zvisina mwero kuti vagamuchire bendamustine Tingjia Li rituximab, 1/3 inogamuchirwa naLu rituximab weNijia Li, 1/3 ndega naLu imatinib. Vatsvaguriri vakatevera kwemwedzi yepakati pemakumi matatu nemasere.
Zvichienzaniswa nebendamustine plus rituximab (74% pamakore maviri), ibrutinib plus rituximab (2% pamakore maviri) uye ibrutinib chete (88 Pagore, 2%) varwere vaive nehurefu hwekuenderera-husina mwero wekupona (pekupedzisira pekupedzisira chidzidzo ). Zvisinei, chidzidzo chacho hachina kuwana musiyano muhuwandu hwekupona kwemapoka matatu mumakore maviri.
Kuenzaniswa nekugamuchira ibrutinib chete, kuwedzera rituximab kune ibrutinib haina kuita sekuvandudza kufungidzira. Pakazara, varwere vakapindura mushe kumatatu ese ekurapa. Iyo yakazara yekupindura mwero wevarwere vanogamuchira bendamustine pamwe rituximab yaive 81%, uye varwere vanowana ibrutinib pamwe rituximab kusvika 93% naLu mumwe murwere achiwana imatinib kurapa yaive 94%.
Kunyangwe iwo mwero wekuparadzwa kwakazara kweleukemia uchishandisa bendamustine pamwe ne rituximab yaive yakakwira, uyu mutsauko hauna kushandukira muhuwandu hwekupona zviri nani kana kudzikisira kudzoka kwemitengo. Saka chenjera zvakanyanya pakusarudza zvinodhaka.
Nekudaro, ibrutinib inosanganisirwa nemhedzisiro mhedzisiro senge atrial fibrillation uye zvisina kujairika moyo mutinhimira izvo zvinowedzera njodzi yekurohwa uye zvimwe zvirwere zvemoyo. Murwere anoteerera kutarisa moyo mamiriro panguva yekushandisa.
https://medicalxpress.com/news/2018-12-ibrutinib-outperforms-chemoimmunotherapy-older-patients.html
